StocksMedium•5 November 2026•
1 min read
Johnson & Johnson Signs Commercial Deal with Oxford BioDynamics for EpiSwitch Orion Platform
Key Facts
1Oxford BioDynamics entered into a commercial agreement with Johnson & Johnson for the use of its EpiSwitch Orion platform.
Oxford BioDynamics entered into a commercial agreement with Johnson & Johnson for the use of its EpiSwitch Orion platform. Benzinga reported that the agreement focuses on the commercial application of the EpiSwitch Orion technology within Johnson & Johnson's operations, specifically as part of a biomarker discovery program in inflammatory bowel disease (IBD).
Johnson & Johnson, trading under the ticker JNJ, closed at $276.32 on November 4, 2026. The stock saw a session range between a low of $267.67 and a high of $277.35 prior to the announcement of this partnership, which marks Oxford BioDynamics' first commercial agreement with a major pharmaceutical company for the use of its cloud-based 3D genomics platform.